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ABSTRAK
Hampir 30% dari populasi dunia telah terkena virus Hepatitis B (HBV) dan 400 juta jiwa telah terinfeksi kronis. 
20-30% dari pembawa virus HBsAg membentuk reaktivasi atau endemisasi HBV, terbentuk dari penggunaan sitotoksik 
atau terapi imunosupresif  untuk pengobatan dari varietas yang lebih luas pada penyakit klinis. Reaktifasi atau fl are adalah 
indikasi pertama dari infeksi HBV. Terkadang sulit untuk membedakan antara Hepatitis B akut atau reaktivasi (fl are). 
Diagnosis yang akurat pada kasus tersebut sangat penting untuk dapat diputuskan apakah akan dilakukan pengobatan atau 
tidak, karena hepatitis B akut tidak membutuhkan persyaratan untuk pengobatan, sedangkan reaktivasi bisa dimungkinkan 
mendapat indikasi lanjut dari diagnosis tersebut. Usaha yang dilakukan untuk deteksi dini, pengobatan dan pencegahan 
reaktivasi atau fl are dari hepatitis B kronis sangat penting untuk mengurangi kesakitan dan kematian.
Kata kunci: Reaktifasi, fl are (pembusukan akut) dari Hepatitis B Kronis, Hepatitis B Kronis, analog nucleos(t)ida
ABSTRACT
Almost 30% of  the world population has been exposed to hepatitis B virus (HBV) and 400 million 
of  these are chronically infected. 20–30% of  HBsAg carriers may develop reactivation or fl are (acute 
exacerbation) of  chronic hepatitis B with elevation of  biochemical levels, high serum HBV DNA level with or 
without sero-coversion to HBeAg. In countries with intermediate or high endemicity for HBV, compounded 
in use cytotoxic or immunosuppressive therapy for the treatment of  a wide variety of  clinical disease, 
reactivation or fl are may be the fi rst presentation of  HBV infection. Sometime it is diffi cult to differentiate 
between acute hepatitis B and reactivation (fl are). Accurate diagnosis in these cases is very important for 
deciding whether to start treatment or not, because acute hepatitis B does not require treatment, while 
reactivation or fl are may take benefi t from it. Effort to early detect, to treat and to prevent the reactivation 
or fl are of  chronic hepatitis B is very crucial to reduce morbidity and mortality. 
Keywords:  Reactivation,  fl are (acute exacerbation) of  chronic hepatitis B,  acute hepatitis B,  nucleos(t)ide 
analogues
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INTRODUCTION
2 billions people or one-third of  the 
world’s population has been infected with 
hepatitis B virus (HBV). It is estimated that 360 
million people have chronic carriers.1 HBV is 
responsible for chronic hepatitis progressing 
to cirrhosis (10–20%), and as much as 20–30% 
of  compensated cirrhosis will lead to hepatic 
decompensate, and 5–15% of  compensated 
cirrhosis will lead to hepatocellular (HCC).2 
The prevalence of  HBV infection varies 
markedly throughout regions of  the world. 
In high endemic areas, like central Asian 
republics, Southeast Asia, Sub-Saharan Africa 
and the Amazon basin, the HBV carrier is 
over 8%. Most of  infections occur during 
infancy or childhood. Globally, perinatal HBV 
transmission accounts for an estimated 21% of  
HBV related deaths. Since the most infections 
in children were asymptomatic, there is a little 
evidence of  acute disease related to HBV, but 
the rates of  chronic liver disease and liver 
cancer in adults are high.1, 3 
Reactivation and fl are of  chronic HBV 
are typically in natural history of  HBV 
infection. Reactivation or fl are of  chronic HBV 
infection can occur in the immune-clearance 
phase affecting 40–50% of  hepatitis HBeAg-
positive patients and 15–30% HBeAg negative 
patients. Although this clinical performance is 
usually transient and asymptomatic, 1-2% of  
patients later develop severe fl are, acute liver 
failure or death.4  
In countries with intermediate or high 
endemicity for HBV, compounded by the recent 
increase in use cytotoxic or immunosuppressive 
therapy for the treatment of  a wide variety of  
clinical disease, fl are of  chronic hepatitis B may 
be the fi rst presentation of  HBV infection. 
Sometime it is diffi cult to differentiate between 
acute hepatitis B and reactivation or fl are of  
chronic hepatitis B. Accurate diagnosis in these 
cases is very important for deciding whether 
to start treatment or not. The reason of  acute 
hepatitis B does not require treatment, while 
reactivation or fl are may take benefi t from 
it.5 An Effort to early detect, to treat and to 
prevent the reactivation or fl are of  chronic 
hepatitis B are very crucial to reduce morbidity 
and mortality. 
The aim of  this review is to understand 
the natural history of  chronic HBV, how to 
manage of  reactivation and fl are of  chronic 
hepatitis B, and to distinguish between acute 
hepatitis and reactivation or fl are of  chronic 
hepatitis B. 
PATHOGENESIS OF HBV
Hepatitis B virus is a noncytopathic, 
hepatotropic virus of  the Hepadnaviridae 
family that causes variable degree of  liver 
disease in human. Infection with HBV can be 
either acute or chronic; while adult infections 
have relatively low rate of  chronicity (around 
5%), neonatal infections usually have a high 
persistence rate (up to 90%). The immune 
responses to HBV antigens are responsible 
both for viral clearance during acute infection 
and for disease pathogenesis.  In patients with 
fulminant HBV infection, rapid clearance is 
achieved after severe injury as a result of  a 
vigorous host immune response. The stronger 
host immune response may influence the 
greater hepatocellular injury, inversely. 6, 7
HBV replicates in hepatocytes to produce 
HBsAg particles and virions. Both types of  
particle can be taken up by antigen presenting 
cells, which degrade the viral proteins to 
peptides that are then presented on the cell 
surface bound to MHC class I or II molecules. 
These peptide antigens can be recognized 
Cahyono et al
42 
by CD8+ or CD4+ cells, respectively, which 
are thereby sensitized.  Virus specifi c CD8+ 
cytotoxic cells (with help CD4+ T cells) can 
recognize viral antigen presented on MHC 
class I chains on infected hepatocytes. This 
recognition reaction can lead to either direct 
lysis of  the infected hepatocyte or the release 
of  interferon-γ and TNA-α, which can down-
regulate viral replication in surrounding 
hepatocytes without direct cell killing.8  
 
NATURAL HISTORY
Phases of  Chronic HBV Infection
To understand the clinical performance 
of  HBV infection, one should know the natural 
history of  this infection that evolved through 
four phases of  chronic HBV infection, although 
not all patients go through every phase.  Those 
with chronic HBV infection may present: (1) 
in a state of  immune tolerance, (2) immune 
clearance or HBeAg-positive chronic hepatitis, 
(3) immune control or inactive HBsAg carrier, 
or (4) immune escape or HBeAg-negative 
chronic hepatitis (see table 1). 9, 10, 11
Immune tolerance phase
Most Asian patients acquire HBV infection 
through the perinatal route or at infancy where 
the immune system is still immature. The 
earlier of  the acquisition infection is the higher 
probability of  developing chronic infection. 
This is the characterized of  these phases: viral 
replication is very high but hepatic damage is 
minimal (liver histological fi ndings minimal or 
no infl ammation), normal serum transaminase 
levels, positive HBeAg, negative anti-HBe and 
high levels of  HBV DNA. A study from Taiwan 
followed 240 patients found only 5% progressed 
to cirrhosis and none to hepatocellular during a 
follow-up period of  10.5 years.11 In perinatal or 
childhood infection, the immune tolerant phase 
may last for fewer than 10 years or more than 20 
years. In infection occurring in adults this phase 
is much shorter because the immune system is 
more mature.  
Immune clearance/HBeAg-positive 
chronic hepatitis
At the age of  20–40 years the majority 
of  chronic hepatitis B patients undergo 
Table 1. The Phases of  Chronic B Virus Infection.9
Phase Liver 
histology
HBV DNA ALT HBeAg
Anti-HBe
Duration Natural history
Immune 
tolerance
Minimal 
infl ammation
>20.000 IU/
ml
Normal Present
Negative
20 - 30 
years
Low risk of  progression 
to advanced liver disease
Immune 
clearance
Variable 
infl ammation
+/- fi brosis
>20.000 IU/
ml (fl uctuating)
Elevated
(fl uctuating)
Present
Positive/ 
negative
Can be 
protracted
Associated with hepatic 
fl ares
Immune 
control or 
inactive 
HBsAg 
carrier state
Minimal 
infl ammation 
and liver 
damage < 2.000 IU/ml Normal Absent Years
Low risk of  advanced 
liver disease
10-20% have reactivation 
of  HBV replication after 
many years
Immune 
escape 
(HBeAg 
negative)
Infl ammation 
and often 
signifi cant 
fi brosis
> 2.000 –
20.000 IU/ml Elevated Absent -
Can enter to immune 
clearance or immune 
control
High risk of  progression 
to advanced liver disease
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immune clearance of  the virus. Due to an 
as yet uncertain trigger, as the host immune 
system matures and begins to recognize HBV-
related epitopes of  the hepatocytes; immune-
mediated hepatocellular injury ensues. This 
phase is characterized by elevation of  serum 
transaminase levels, high levels of  serum 
HBV DNA (but usually lower than during 
the immune tolerance phase), and histological 
findings of  active inflammation and often 
fi brosis in the liver. A hallmark of  this phase is 
fl are of  aminotransferases, which are believed 
to be the manifestations of  immune-mediated 
lysis of  infected hepatocytes secondary to 
increased T-cell response to HBcAg and 
HBeAg. Most patients remain asymptomatic, 
making it diffi cult to detect the transition from 
immune tolerance phase based on clinical 
ground alone. However, some patients present 
with a symptomatic flare of  hepatitis that 
mimics acute hepatitis or even with fulminant 
hepatitis failure. It is now recognized that 
duration of  this phase and frequency and 
severity of  the fl ared, correlate with the risk 
of  cirrhosis and hepatocellular. 9, 11 
Immune control or inactive HBsAg carrier 
state
HBeAg is marker of  high viral replication 
and associated with disease progression. 
HBeAg sero-conversion is considered as a key 
event in the evolution of  chronic hepatitis B.  
After sero-convesion, most patients remain 
negative for HBeAg and positive for anti-HBe. 
Sero-conversion is usually accompanied by 
stabilization of  hepatitis. It characterized by 
normalization of  ALT levels and decreases 
in HBV DNA to low or undetectable levels 
and depending on the assays used.  This 
condition is commonly referred as the inactive 
carrier state. An estimated 20–30% of  HBsAg 
carriers may develop reactivation of  hepatitis 
B with elevation of  biochemical levels, high 
serum HBV DNA level with or without sero-
conversion to HBeAg.12, 13 
Immune escape or reactivation of  HBV 
replication or HBeAg negative chronic 
hepatitis B phase
Chronic hepatitis may recur in up to 
one-third of  inactive HBV carriers without 
reversion of  HBeAg in their serum. Some of  
these carriers are likely infected with one of  
the HBV variants that cannot express HBeAg 
because of  the precore or core-promoter 
regions mutations of  the HBV genome. 
This phase is characterized by the absence 
of  HBeAg, elevated levels of  serum ALT, 
and histological fi ndings of  continued necro-
infl ammation of  the liver. Compared to the 
HBeAg-positive chronic hepatitis, patients with 
HBeAg negative chronic hepatitis are generally 
older. The patients also have more advanced 
disease as evidenced by liver histology because 
this represents a later phase in the course of  
chronic HBV infection. Serum HBV DNA 
levels are lower than in HBeAg positive patients 
but may reach 108-9 IU/ml. The hallmark of  
this phase is its fl uctuating course, 64% had 
fl uctuating ALT levels during monitoring for 
a median period of  21 months. 7, 9
Phases of  HBV Reactivation
According to the American Association 
for the Study of  Liver Disease (AASLD)14, 
fl are (acute exacerbation) of  chronic hepatitis 
B is defi ned as an intermittent elevation of  
aminotransferase activity to more than 10 times 
upper limit of  normal and more than twice the 
baseline value. And reactivation of  chronic 
hepatitis B is a well-characterized syndrome 
marked by abrupt reappearance or rise of  HBV 
DNA in the serum of  patient with previously 
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inactive or resolved (previous HBV infection 
without further virology, biochemical or 
histological evidence of  active virus infection 
or disease) HBV infection.14,15 Reactivation is 
also often, but not always, accompanied by 
reappearance of  disease activity or a fl are of  
hepatitis.15  Based on the understanding of  the 
pathogenesis, HBV reactivation is best defi ned 
as an increase of  HBV viral replication from 
a low to high replicate level in patients with 
chronic or past HBV infection (usually serum 
HBV DNA increase more than 1 log higher 
than the pre-exacerbation baseline).16  
Asian-Pacifi c consensus described that 
one of  the cause of  severe fl are that manifest 
as acute on chronic liver failure is reactivation 
of  hepatitis B. It characterized by jaundice and 
coagulopathy, complicated within 4 weeks by 
ascites or encephalopathy in a patient with 
previously diagnosed or undiagnosed chronic 
liver disease.17 
There are two kinds of  fl are occurred in 
chronic hepatitis B. The fi rst one is exacerbation 
in the immune-clearance phase. The second one 
occurred after inactive carrier phase or in immune 
escape phase. The exacerbation occurred in 
immune escape phase (HBeAg negative phase) 
is called reactivation (fi gure 1).18 
Reactivation and fl are of  chronic hepatitis 
B can be spontaneously, but (especially for 
reactivation) most commonly triggered 
by immunosuppressive therapy cancer, 
autoimmune disease, organ transplantation 
and superimposed infections.4, 14 The most 
commonly reported types of  chemotherapy 
related to HBV reactivation are those used 
for the treatment of  hematologic malignancy, 
such as acute leukemia, myelo-proliferative 
disorders, lympho-proliferative disorders, and 
plasma cell dyscrasias. 16
Several studies have confi rmed of  HBV 
reactivation following chemotherapy, and 
the median interval between the initiation of  
chemotherapy and onset of  reactivation is 4 
months (range, 1–9 months). The rate of  HBV 
reactivation ranges from 24–88% in patients 
with chronic HBV who have positive serum 
HBsAg, and from 3–22% in patients who are 
HBcAb positive. The mortality rate in HBV 
reactivation ranges from 23–71%.19
Spontaneous fl are of  chronic hepatitis B 
infection was seen with cumulative probability 
of  15–37% after 4 years of  follow up. The short-
term prognosis of  patients with spontaneous 
severe of  fl are to acute on chronic liver failure-
like presentation is extremely poor, with a 
Figure 1. The Natural history of  chronic hepatitis B infection.18
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mortality rate ranging from 30–70%.20  There 
are three phases of  HBV reactivation, but 
not all the patients have all three phases (see 
table 2).14 Reactivation starts with the abrupt 
increase in viral replication that typically occurs 
soon after initiating immune suppression or 
chemotherapy. The increasing degree in viral 
replication is measured by the rise in HBV 
DNA in serum. In patients without HBeAg, 
this marker may reappear in the serum. The 
second phase starts when immune-suppression 
is withdrawn or decrease and hepatocellular 
injury or hepatitis arises, as shown by rises in 
serum aminotransferase levels and, in more 
severe instances, symptoms and jaundice. 
During this phase, HBV DNA levels may 
start to fall. The third phase of  reactivation 
is recovery, as the evidence of  liver injury 
resolves and HBV markers return to baseline 
values. 
DIAGNOSIS 
Although HBV react ivat ion can 
occur spontaneously, it usually occurs after 
chemotherapy or immune-suppression. 
The clinical presentation cases can vary, 
ranging from subclinical, asymptomatic 
course to severe acute hepatitis and even 
death. Although reactivation of  HBV is 
mainly found in HBsAg positive patients, it 
can be observed in serologically recovered 
anti-HBc-positive, HBsAg-negative patients.21 
The current generally accepted defi nition of  
HBV reactivation following chemotherapy, 
is the development of  hepatitis with a serum 
ALT greater than three times the upper 
limit of  normal, or an absolute increase of  
100 IU/L, associated with a demonstrable 
increase in HBV DNA by at least a 10-fold, 
or an absolute increase to > 108 IU/mL.22 The 
typical presentation of  severe fl are or acute 
exacerbation is a short onset of  jaundice and 
very high ALT level, sometimes preceded by 
prodromal constitutional symptoms, in patient 
with chronic HBV. Patient that suffered from 
acute on chronic liver failure is characterized by 
jaundice and coagulopathy, complicated within 
4 weeks by ascites and or encephalopathy.17
The symptoms of  severe fl are of  chronic 
hepatitis B can be similar to those of  acute 
hepatitis B. Hence, severe flare might be 
misdiagnosis as acute hepatitis B in some 
case. In areas of  intermediate to high HBV 
endemicity, endemic for chronic hepatitis 
B, reactivation or fl are of  chronic hepatitis 
B accounts for 27–70% of  presumed acute 
hepatitis B. So it is important to understand 
the factors that differentiated severe flare 
of  chronic hepatitis B from acute hepatitis 
B. A detailed history taking, IgM anti-HBc 
Table 2.  Three Phases of  HBV Reactivation14  
Phase Feature Diagnostic Markers Comments
1 Increase in viral replication HBV DNA
HBeAg
HBsAg
Rise of  > 1 log 
10
  IU/ml 
In HBeAg negative 
Reverse sero-conversion
2 Appearance of  disease activity ALT
Symptoms
Jaundice
Rise of  > 3 times baseline
Indicative of  more severe injury
3 Recovery HBV DNA
ALT
HBsAg
Fall to baseline values
Fall to baseline values
Maybe cleared late
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titer, HBV level and follow up HBsAg after 6 
months are clue for diagnostic.   
 An Indian study suggest that a low 
titer of  IgM anti-HBc (< :1000) and high HBV 
DNA level (> 141.500 copies/ml) are useful to 
identify severe acute exacerbation of  chronic 
HBV from acute hepatitis B.23
 
THERAPY
The severity of  the fl are depends on the 
state of  underlying liver disease. As patients 
with severe fl are of  chronic hepatitis B may not 
have underlying cirrhosis, they may recover to 
relatively normal liver function in contrast to 
those with end-stage-cirrhosis.4, 24 It is important 
to recognize this clinical presentation of  
chronic hepatitis B. In severe fl are of  chronic 
hepatitis B when immune clearance is already 
excessive, interferon-based treatment may be 
dangerous in further aggravating the hepatic 
decompensating and thus contraindicated. 
Most data in the published work involves the 
use of  lamivudine to treat this condition.24 
An aggressive supportive treatment and 
discontinuation of  cytotoxic chemotherapy 
has been the mainstay of  treatment. 25
Severe fl are of  chronic HBV patient need 
an intensive supportive care including close 
monitoring and treatment complication. For 
antiviral treatment to be effective, it should 
be administered early, preferably before 
serum bilirubin has gone up too high to ‘the 
point of  no return’. After a median treatment 
period of  6 weeks, all of  the 25 patients with 
pre-therapy bilirubin level < 20 mg/dl in 
the treatment group (lamivudine 150 mg/
day) group survived, while fi ve (20%) of  20 
patients in controlled group died (p= 0.013).26 
The defi nitive treatment for severe fl are of  
chronic hepatitis B is liver transplantation.4 
In uncertain cases of  acute hepatitis B vs. 
severe fl are of  chronic hepatitis B, one should 
manage these patients as severe flare  and 
retested HBsAg after 6 months. Antiviral 
therapy is not indicated in the most patients 
with acute hepatitis, but may be indicated in 
certain groups of  patients: (1) patients with 
fulminant hepatitis B, hepatic encephalopathy, 
persistent symptoms or marked jaundice 
Table 3. Factors to Differentiate Severe Flare of  Chronic Hepatitis B
from Acute  Hepatitis B 24
Factor
severe acute exacerbation of  
chronic hepatitis B
acute hepatitis B
Useful history Past history of  chronic hepatitis B
Family history of  chronic hepatitis B
Recent at risk blood, percutaneous or 
sexual exposure to HBV
Ig M anti-HBc titer Negative to low (< 1: 1000) High (> 1 : 1000 )
HBV DNA level High (> 100 000 copies/ml) Low  (< 100 000 copies/ml)
Histology Evidence of  chronicity No evidence of  chronicity
Follow up HBsAg after 6 months Positive Negative in over 95% of  patients
Uncertain :
· Basal core promoter mutation
· Precore stop codon mutation
Present
Present
Absent
Absent
Not useful :
· Symptoms and signs
· Alanine transaminase
Prodromal symptom
Jaundice and itching
Abdominal discomfort
Very high
Prodromal symptom
Jaundice and itching
Abdominal discomfort
Very high
The Journal of  Internal Medicine, Acta Interna, Volume 4, Number 1, June 2014: 40-49
47 
(bilirubin >10 mg/dL) for more than 4 weeks 
after presentation, or those who are immune-
compromised, have concomitant infection 
with hepatitis C or D, or have pre-existing live 
disease. 4 
PREVENTION
 The Centers for Disease Control and 
Prevention (CDC) recommends testing patients 
for HBsAg, anti-HBc and anti-HBs before 
they receive immunosuppressive therapy. The 
Practice Guideline of  the American (AASLD) 
also recommend of  HBV screening before 
beginning immunosuppressive therapy.27 
Although the CDC recommendations to test 
HBV before starting immunosuppressive 
therapy, surveys of  oncologists have found 
that only 13–19% routinely test patients 
before initiating the immune-suppressive 
therapy.28 Day Fl et al (2011) reported that 
the majority of  Australian medical oncologist 
have not adapted universal screening before 
chemotherapy. Oncologists who did not screen 
most commonly cited inadequate evidence for 
a benefi t of  screening (72%).29 Two decade 
ago, occult B hepatitis infection/OBI (anti 
HBc and or anti HBs positive, HBsAg negative 
with HBV DNA < 200 IU/mL) and resolved 
or past hepatitis B were not recognized to be 
at risk of  HBV reactivation when receiving 
conventional systemic chemotherapy. But 
now patients with OBI represent an important 
group with a high risk for reactivation.30
One potential means of  minimizing the 
risk of  HBV reactivation is the avoidance 
of  cor t icosteroid therapy as par t  of  
chemotherapeutic/antiemetic regimes in 
HBsAg carriers.25 Closely monitoring and 
evaluating chronic hepatitis B is an important 
action to prevent and to minimize of  fl are. 
Because viral replication occurs before clinical 
evidence of  hepatitis it raises the possibility 
of  using lamivudine in prophylactic manner 
before the administration of  chemotherapy.25 
A systematic studied evaluated that 550 
HBsAg-positive patients receiving a cancer 
therapy. In patients who did not receive 
prophylactic antiviral therapy: 36.8% had 
HBV reactivation, 33.44% had HBV-related 
hepatitis, 13% had liver failure, and 5.5% died. 
Prophylactic use of  lamivudine decreased the 
risk for HBV reactivation and HBV-related 
hepatitis by 79–100%. 27 Elevated serum 
ALT level, serum HBV DNA >105 copies/
ml, positive serum HBeAg are risk factors for 
HBV reactivation. HBsAg positive patients 
undergoing chemotherapy should be treated 
with lamivudine 100 mg/day orally for at least 
3 months after completion of  chemotherapy, 
when white blood count has returned to pre-
chemotherapy level. A high pre-chemotherapy 
HBV DNA (> 104 copies/ml) was the most 
important risk factor for HBV reactivation 
after withdrawal of  preemptive lamivudine. 
Therefore, continue lamivudine for the longer 
period time until there is evidence of  sero-
conversion of  HBeAg or HBsAg and closely 
monitors every 4 weeks. 16, 31  
SUMMARY
The presentation of  reactivation or fl are 
of  chronic hepatitis B is quite common and is 
often diffi cult to clinically and biochemically 
differentiate from acute hepatitis B. A low 
titer of  IgM anti-HBc (< 1:1000) and high 
HBV DNA level (> 141.500 copies/mL) are 
useful to identify fl are of  chronic HBV from 
acute hepatitis B. In uncertain cases of  acute 
hepatitis B vs. severe fl are of  chronic hepatitis 
B, one should manage these patients as fl are 
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and retested HBsAg after 6 months. Antiviral 
therapy is not indicated in the most patients 
with acute hepatitis, but may be indicated 
Although HBV react ivat ion can 
occur spontaneously, it usually occurs after 
chemotherapy or immune-suppression. It is 
recommended to screen HBsAg and Anti-HBc 
before beginning immunosuppressive therapy. 
When there is positive of  HBV infection, 
prophylactic use of  lamivudine should be 
started, because it decreases the risk for HBV 
reactivation and HBV-related hepatitis.
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